Premium
Current use of monoclonal antibodies in the treatment of multiple myeloma
Author(s) -
Varga Cindy,
Maglio Michelle,
Ghobrial Irene M.,
Richardson Paul G.
Publication year - 2018
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.15121
Subject(s) - daratumumab , medicine , multiple myeloma , lymphoma , oncology , monoclonal antibody , malignancy , disease , lenalidomide , clinical trial , bortezomib , immunology , antibody
Summary Multiple myeloma ( MM ) is the second most common haematological malignancy after non‐Hodgkin lymphoma. Despite the improvement in outcomes over the last decade with the introduction of novel therapies, such as immunomodulatory agents ( IM iDs) and proteasome inhibitors ( PI s), MM remains an incurable disease. Patients who are both refractory to IM iDs and PI s carry a particularly dismal prognosis. The development of targeted therapy in the form of monoclonal antibodies has shifted the treatment paradigm of this disease, resulting in unprecedented response rates, even among the highest‐risk patients. In this review, we will summarize the mechanism of action and provide an overview of the clinical trials that have led to the US Food and Drug Administration approval of Daratumumab and Elotuzumab, and their current use in the treatment of MM .